Moderna’s COVID-19 vaccine presented new safety data from an early trial that stimulates the immune system of older people.
The vaccine was tested on 10 adults between the ages of 56 and 70, and 10 elderly adults aged 71 and older. Each participant received two 100 microgram doses of the vaccine 28 days apart. The vaccine produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and T-cells, Moderna said in its results, which have not yet been published in a peer-reviewed journal.
Additionally, the antibodies that were produced were higher than those seen in people who have recovered from COVID-19.
The vaccine appeared to be well tolerated, with no serious adverse events reported. Some patients reported fatigue, chills, headaches, and pain at the injection site, though the majority of symptoms were resolved within two days, the company said.
The vaccine from Moderna is one of several in development to fight the coronavirus, which has infected more than 23.9 million people worldwide and killed at least 820,100, according to data compiled by Johns Hopkins University.